Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seltorexant - Janssen Research & Development/Minerva Neurosciences

Next Previous
X
Search
Drug Profile

Seltorexant - Janssen Research & Development/Minerva Neurosciences

Alternative Names: JNJ-42847922; JNJ-7922; MIN-202

Latest Information Update: 04 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Minerva Neurosciences
  • Class Antidepressants; Fluorinated hydrocarbons; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Phase II Alzheimer's disease; Insomnia
  • No development reported Sleep apnoea syndrome

Most Recent Events

  • 29 May 2024 Efficacy and adverse event data from a phase III trial in Major depressive disorder released by Johnson & Johnson
  • 28 May 2024 No recent reports of development identified for phase-I development in Major depressive disorder(Adjunctive treatment) in Germany (PO, Tablet)
  • 27 May 2024 Janssen terminates the phase I trial in Major depressive disorder (Adjunctive treatment, In children, In adolescents, Treatment-experienced) due to sufficient data for the seltorexant pediatric program, as per discussions on pediatric strategy with HAs in USA, Spain, Italy and UK (PO) (NCT04951609) (EudraCT2021-000567-77)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top